With the Bohle Uni Cone BUC ® process, L.B. Bohle can protect a new development method for precise coating of particles as a utility model right now. "This method works much more accurately and evenly than the conventional Wurster process", says the CEO Lorenz Bohle.
Bohle Fluid Bed Sytsem BFS - Bohle Uni Cone BUC®
With the Bohle Uni Cone BUC ® process, L.B. Bohle can protect a new development method for precise coating of particles as a utility model right now. “This method works much more accurately and evenly than the conventional Wurster process”, says the CEO Lorenz Bohle.
The Wurster process is used, when small particle, so called pellets, must be coated. Biggest weaknesses are hardly calculable setting parameters and the spray nozzles in the bottom.
"We have developed two major changes that solve both problems of the Wurster process", says Bohle. A sloping floor and a conical tip in the center provide a uniform turbulence of the product. Simultaneously, the coating substance is spray to lateral nozzles. "We thus reach a hitherto possible coating uniformity, the losses are under one percent in a very complex process", said Bohle. Furthermore the Bohle Uni Cone BUC ® guarantees high yields in the final product due to absence of particle twinning effects. "The losses are under one percent in a very complex process."
The tangential nozzles have also enhanced quality advantages in handling.
By this reasons using the tangential BFS represents state of the art in pharmaceutical manufacturing for particle coating, granulation and drying.
Contact information:
Tobias Borgers
Head of Marketing
t.borgers@lbbohle.de
+49 2524 – 9323 150
+49 2524 – 93 23 399
www.lbbohle.com
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.